Savara (SVRA) Assets (2010 - 2026)
Savara (SVRA) posted quarterly Assets of $221.6 million for Q1 2026, up 17.08% year-over-year from $189.3 million in Q1 2025, and down 12.54% quarter-over-quarter from $253.4 million in Q4 2025.
Savara (SVRA) Assets (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Assets for 17 consecutive years, with $221.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 17.08% year-over-year to $221.6 million; the TTM figure through Mar 2026 stood at $221.6 million (up 17.08% YoY), while the FY2025 annual figure was $253.4 million, up 19.05% from the prior year.
- Assets eased to $221.6 million in Q1 2026 per SVRA's latest filing, from $253.4 million in the prior quarter.
- Across five years, Assets topped out at $253.4 million in Q4 2025 and bottomed at $119.8 million in Q2 2023.
- Historically, Assets has averaged $172.8 million across 5 years, with a median of $163.8 million in 2025.
- Annual changes were most pronounced in 2024 — Assets surged 31.17% — and 2025, when it slumped 40.99%.
- Savara's Assets stood at $139.8 million in 2022, then increased by 27.03% to $177.6 million in 2023, then grew by 19.89% to $212.9 million in 2024, then grew by 19.05% to $253.4 million in 2025, then dropped by 12.54% to $221.6 million in 2026.
- Business Quant data shows SVRA's Assets at $221.6 million in Q1 2026, $253.4 million in Q4 2025, and $140.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 192.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.14 Mn |
| Mar 31, 2026 | 221.65 Mn |
| Dec 31, 2025 | 253.44 Mn |
| Sep 30, 2025 | 140.92 Mn |
| Jun 30, 2025 | 163.77 Mn |
| Mar 31, 2025 | 189.32 Mn |
| Dec 31, 2024 | 212.88 Mn |
| Sep 30, 2024 | 238.82 Mn |
| Jun 30, 2024 | 139.67 Mn |
| Mar 31, 2024 | 158.30 Mn |
| Dec 31, 2023 | 177.56 Mn |
| Sep 30, 2023 | 182.07 Mn |
| Jun 30, 2023 | 119.83 Mn |
| Mar 31, 2023 | 129.36 Mn |
| Dec 31, 2022 | 139.78 Mn |
| Sep 30, 2022 | 147.76 Mn |
| Jun 30, 2022 | 156.78 Mn |
| Mar 31, 2022 | 166.21 Mn |
| Dec 31, 2021 | 176.60 Mn |
| Sep 30, 2021 | 187.27 Mn |